AZENTA INC (AZTA) Stock Fundamental Analysis
NASDAQ:AZTA - Nasdaq - US1143401024 - Common Stock - Currency: USD
AZTA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 56 industry peers in the Life Sciences Tools & Services industry. No worries on liquidiy or solvency for AZTA as it has an excellent financial health rating, but there are worries on the profitability. AZTA is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year AZTA was profitable.
AZTA had a positive operating cash flow in the past year.
In multiple years AZTA reported negative net income over the last 5 years.
Of the past 5 years AZTA 4 years had a positive operating cash flow.
1.2 Ratios
The Return On Assets of AZTA (-3.20%) is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -3.84%, AZTA is in the better half of the industry, outperforming 60.71% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.2% | ||
| ROE | -3.84% | ||
| ROIC | N/A |
ROA(3y)16.36%
ROA(5y)11.87%
ROE(3y)17.86%
ROE(5y)13.45%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AZTA's Gross Margin of 43.08% is in line compared to the rest of the industry. AZTA outperforms 44.64% of its industry peers.
AZTA's Gross Margin has been stable in the last couple of years.
AZTA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 43.08% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.44%
GM growth 5Y-0.19%
2. Health
2.1 Basic Checks
AZTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AZTA has been reduced compared to 1 year ago.
The number of shares outstanding for AZTA has been reduced compared to 5 years ago.
Compared to 1 year ago, AZTA has a worse debt to assets ratio.
2.2 Solvency
AZTA has an Altman-Z score of 4.20. This indicates that AZTA is financially healthy and has little risk of bankruptcy at the moment.
AZTA has a Altman-Z score of 4.20. This is in the better half of the industry: AZTA outperforms 76.79% of its industry peers.
AZTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.2 |
ROIC/WACCN/A
WACC10.55%
2.3 Liquidity
AZTA has a Current Ratio of 3.22. This indicates that AZTA is financially healthy and has no problem in meeting its short term obligations.
AZTA has a Current ratio of 3.22. This is comparable to the rest of the industry: AZTA outperforms 53.57% of its industry peers.
A Quick Ratio of 2.84 indicates that AZTA has no problem at all paying its short term obligations.
AZTA's Quick ratio of 2.84 is in line compared to the rest of the industry. AZTA outperforms 55.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.22 | ||
| Quick Ratio | 2.84 |
3. Growth
3.1 Past
AZTA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 42.42%, which is quite impressive.
AZTA shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -12.07% yearly.
AZTA shows a decrease in Revenue. In the last year, the revenue decreased by -2.75%.
The Revenue has been decreasing by -3.41% on average over the past years.
EPS 1Y (TTM)42.42%
EPS 3Y-45.83%
EPS 5Y-12.07%
EPS Q2Q%0%
Revenue 1Y (TTM)-2.75%
Revenue growth 3Y8.51%
Revenue growth 5Y-3.41%
Sales Q2Q%-9.88%
3.2 Future
Based on estimates for the next years, AZTA will show a very strong growth in Earnings Per Share. The EPS will grow by 29.43% on average per year.
AZTA is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.23% yearly.
EPS Next Y9.63%
EPS Next 2Y38.73%
EPS Next 3Y37.52%
EPS Next 5Y29.43%
Revenue Next Year-8.96%
Revenue Next 2Y-2.28%
Revenue Next 3Y0.06%
Revenue Next 5Y2.23%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 71.21 indicates a quite expensive valuation of AZTA.
AZTA's Price/Earnings ratio is in line with the industry average.
AZTA's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.41.
A Price/Forward Earnings ratio of 42.41 indicates a quite expensive valuation of AZTA.
The rest of the industry has a similar Price/Forward Earnings ratio as AZTA.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.19, AZTA is valued a bit more expensive.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 71.21 | ||
| Fwd PE | 42.41 |
4.2 Price Multiples
62.50% of the companies in the same industry are more expensive than AZTA, based on the Enterprise Value to EBITDA ratio.
The rest of the industry has a similar Price/Free Cash Flow ratio as AZTA.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 59.16 | ||
| EV/EBITDA | 35.98 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates AZTA does not grow enough to justify the current Price/Earnings ratio.
AZTA's earnings are expected to grow with 37.52% in the coming years. This may justify a more expensive valuation.
PEG (NY)7.39
PEG (5Y)N/A
EPS Next 2Y38.73%
EPS Next 3Y37.52%
5. Dividend
5.1 Amount
AZTA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
33.47
-0.68 (-1.99%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners117.02%
Inst Owner ChangeN/A
Ins Owners0.65%
Ins Owner Change3.5%
Market Cap1.53B
Analysts51.67
Price Target39.1 (16.82%)
Short Float %10.26%
Short Ratio4.65
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.64%
Min EPS beat(2)-29.97%
Max EPS beat(2)37.26%
EPS beat(4)3
Avg EPS beat(4)50.46%
Min EPS beat(4)-29.97%
Max EPS beat(4)122.72%
EPS beat(8)7
Avg EPS beat(8)229.99%
EPS beat(12)10
Avg EPS beat(12)156.19%
EPS beat(16)13
Avg EPS beat(16)121%
Revenue beat(2)0
Avg Revenue beat(2)-0.65%
Min Revenue beat(2)-1.07%
Max Revenue beat(2)-0.22%
Revenue beat(4)1
Avg Revenue beat(4)-0.27%
Min Revenue beat(4)-1.7%
Max Revenue beat(4)1.9%
Revenue beat(8)4
Avg Revenue beat(8)0.73%
Revenue beat(12)5
Avg Revenue beat(12)-0.93%
Revenue beat(16)7
Avg Revenue beat(16)-8.04%
PT rev (1m)0%
PT rev (3m)-30.3%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-7%
EPS NY rev (1m)0%
EPS NY rev (3m)-11.87%
Revenue NQ rev (1m)0.19%
Revenue NQ rev (3m)0.11%
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)0.51%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 71.21 | ||
| Fwd PE | 42.41 | ||
| P/S | 2.42 | ||
| P/FCF | 59.16 | ||
| P/OCF | 25.66 | ||
| P/B | 0.9 | ||
| P/tB | 1.69 | ||
| EV/EBITDA | 35.98 |
EPS(TTM)0.47
EY1.4%
EPS(NY)0.79
Fwd EY2.36%
FCF(TTM)0.57
FCFY1.69%
OCF(TTM)1.3
OCFY3.9%
SpS13.84
BVpS37.17
TBVpS19.82
PEG (NY)7.39
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.2% | ||
| ROE | -3.84% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 43.08% | ||
| FCFM | 4.09% |
ROA(3y)16.36%
ROA(5y)11.87%
ROE(3y)17.86%
ROE(5y)13.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.44%
GM growth 5Y-0.19%
F-Score7
Asset Turnover0.31
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 43.02% | ||
| Cap/Sales | 5.33% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 190.21% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.22 | ||
| Quick Ratio | 2.84 | ||
| Altman-Z | 4.2 |
F-Score7
WACC10.55%
ROIC/WACCN/A
Cap/Depr(3y)77.14%
Cap/Depr(5y)74.64%
Cap/Sales(3y)8.52%
Cap/Sales(5y)9.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.42%
EPS 3Y-45.83%
EPS 5Y-12.07%
EPS Q2Q%0%
EPS Next Y9.63%
EPS Next 2Y38.73%
EPS Next 3Y37.52%
EPS Next 5Y29.43%
Revenue 1Y (TTM)-2.75%
Revenue growth 3Y8.51%
Revenue growth 5Y-3.41%
Sales Q2Q%-9.88%
Revenue Next Year-8.96%
Revenue Next 2Y-2.28%
Revenue Next 3Y0.06%
Revenue Next 5Y2.23%
EBIT growth 1Y41.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1003.3%
EBIT Next 3Y150.21%
EBIT Next 5YN/A
FCF growth 1Y105.18%
FCF growth 3Y-48.98%
FCF growth 5Y-28.07%
OCF growth 1Y113.28%
OCF growth 3Y-30.52%
OCF growth 5Y-11.17%